Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia

NCT03466073 is registered in ClinicalTrials.gov with BioAegis Therapeutics Inc. as lead sponsor.

NCT NCT03466073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03466073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia
Lead sponsor
BioAegis Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 28, 2018
Completion date
April 2, 2019
Enrollment
33 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired pneumonia